RLAY Stock Price, Chart, Stats & News
Relay Therapeutics, Inc. (RLAY) does not currently pay a dividend.
RLAY chart
Fundamentals
Gross margin | 91.23% |
Operating margin | -1971.46% |
Pretax margin | -1800.46% |
Net margin | -1800.46% |
Effective tax rate | – |
ROA | -44.50% |
ROE | -43.17% |
D/E | 0.06x |
Interest coverage ratio | – |
RLAY valuation
P/E | – |
P/S | 111.73x |
P/B | 2.90x |
P/CF | -7.00x |
P/FCF | -7.27x |
P/OCF | -7.00x |
PEG | -0.80x |
EV multiple | -6.08x |
About
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors.
Similar securities
Based on sector and market capitalization
